SecBot SecBot
SECBOTREPLAY Home › Report › TIL

TIL · Instil Bio reported its Q4 and full-year 2025 financial results,…

Instil Bio · PRESS-RELEASE filed Mar 27, 2026 at 07:00 ET

At the news

MIXEDIMPACT 5/10

PRESS-RELEASE filed Mar 27, 2026 at 07:00 ET

Instil Bio reported its Q4 and full-year 2025 financial results, showing a reduced net loss compared to the prior year despite declining cash reserves. The company discontinued development of AXN-2510 and is now focusing on external growth through acquisitions and in-licensing, with a cash runway expected to fund operations beyond 2027.

  • Net loss for full year 2025 was $71.37 million ($10.70 per share), improved from $74.14 million ($11.39 per share) in 2024.
  • Cash, cash equivalents, restricted cash, and marketable securities declined to $76.3 million as of December 31, 2025, from $115.1 million a year earlier.
  • The company discontinued AXN-2510 development and terminated its collaboration with ImmuneOnco Biopharmaceuticals.
  • Instil is now pursuing acquisitions and in-licensing opportunities to build a new pipeline.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access